Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.

Kornbluth RS, Stempniak M, Stone GW.

Int Rev Immunol. 2012 Aug;31(4):279-88. doi: 10.3109/08830185.2012.703272. Review.

2.

Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.

Feder-Mengus C, Schultz-Thater E, Oertli D, Marti WR, Heberer M, Spagnoli GC, Zajac P.

Hum Gene Ther. 2005 Mar;16(3):348-60.

PMID:
15812230
3.

Tuning of CD40-CD154 interactions in human B-lymphocyte activation: a broad array of in vitro models for a complex in vivo situation.

Néron S, Nadeau PJ, Darveau A, Leblanc JF.

Arch Immunol Ther Exp (Warsz). 2011 Feb;59(1):25-40. doi: 10.1007/s00005-010-0108-8. Epub 2011 Jan 14. Review.

PMID:
21234809
4.

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.

Carpenter EL, Mick R, Rüter J, Vonderheide RH.

J Transl Med. 2009 Nov 11;7:93. doi: 10.1186/1479-5876-7-93.

5.

Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.

Li Q, Grover AC, Donald EJ, Carr A, Yu J, Whitfield J, Nelson M, Takeshita N, Chang AE.

J Immunol. 2005 Aug 1;175(3):1424-32.

6.

Production and characterization of agonistic monoclonal antibodies against chicken CD40.

Chen CH, Abi-Ghanem D, Njongmeta L, Bray J, Mwangi W, Waghela SD, McReynolds JL, Ing NH, Berghman LR.

Dev Comp Immunol. 2010 Nov;34(11):1139-43. doi: 10.1016/j.dci.2010.06.014. Epub 2010 Jul 3.

PMID:
20599554
7.

The use of agonistic anti-CD40 therapy in treatments for cancer.

Khong A, Nelson DJ, Nowak AK, Lake RA, Robinson BW.

Int Rev Immunol. 2012 Aug;31(4):246-66. doi: 10.3109/08830185.2012.698338. Review.

PMID:
22804570
8.

CD40 activation as potential tool in malignant neoplasms.

Ottaiano A, Pisano C, De Chiara A, Ascierto PA, Botti G, Barletta E, Apice G, Gridelli C, Iaffaioli VR.

Tumori. 2002 Sep-Oct;88(5):361-6. Review.

PMID:
12487551
9.

The role of CD40 and CD154/CD40L in dendritic cells.

Ma DY, Clark EA.

Semin Immunol. 2009 Oct;21(5):265-72. doi: 10.1016/j.smim.2009.05.010. Epub 2009 Jun 12. Review. Erratum in: Semin Immunol. 2010 Jun;22(3):190.

10.

Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.

Richman LP, Vonderheide RH.

Cancer Immunol Res. 2014 Jan;2(1):19-26. doi: 10.1158/2326-6066.CIR-13-0152.

11.

In this issue: harnessing immunity against difficult targets, through the CD40-CD40L pathway.

Kornbluth RS, Bot A.

Int Rev Immunol. 2012 Aug;31(4):243-5. doi: 10.3109/08830185.2012.702511.

PMID:
22804569
12.

A membrane-bound form of IL-4 enhances proliferation and antigen presentation of CD40-activated human B cells.

Park JY, Yoon SH, Kim EK, Yun SO, Park MY, Sohn HJ, Kim TG.

Immunol Lett. 2008 Feb 15;116(1):33-40. Epub 2007 Dec 3.

PMID:
18096249
13.

CD40-activated B cells contribute to mesothelioma tumor regression.

Jackaman C, Cornwall S, Graham PT, Nelson DJ.

Immunol Cell Biol. 2011 Feb;89(2):255-67. doi: 10.1038/icb.2010.88. Epub 2010 Jul 13.

PMID:
20628372
14.

Molecular mechanism and function of CD40/CD40L engagement in the immune system.

Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ.

Immunol Rev. 2009 May;229(1):152-72. doi: 10.1111/j.1600-065X.2009.00782.x. Review.

15.

Generation of human CD40-activated B cells.

Liebig TM, Fiedler A, Zoghi S, Shimabukuro-Vornhagen A, von Bergwelt-Baildon MS.

J Vis Exp. 2009 Oct 16;(32). pii: 1373. doi: 10.3791/1373.

16.

Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.

Hassan SB, Sørensen JF, Olsen BN, Pedersen AE.

Immunopharmacol Immunotoxicol. 2014 Apr;36(2):96-104. doi: 10.3109/08923973.2014.890626. Epub 2014 Feb 21. Review.

PMID:
24555495
18.

CD40 stimulation induces differentiation of acute lymphoblastic leukemia cells into dendritic cells.

Luczyński W, Stasiak-Barmuta A, Iłendo E, Krawczuk-Rybak M, Malinowska I, Mitura-Lesiuk M, Parfieńczyk A, Szymański M.

Acta Biochim Pol. 2006;53(2):377-82. Epub 2006 May 29.

19.

Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.

von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL.

Blood. 2002 May 1;99(9):3319-25.

20.

The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells.

Shimabukuro-Vornhagen A, Draube A, Liebig TM, Rothe A, Kochanek M, von Bergwelt-Baildon MS.

J Exp Clin Cancer Res. 2012 May 16;31:47. doi: 10.1186/1756-9966-31-47.

Supplemental Content

Support Center